^
    Back
    Association details:
    Biomarker:PIK3CA mutation + PTEN deletion
    Cancer:Solid Tumor
    Drug:Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

    Published date:
    02/08/2022
    Excerpt:
    Arm Z1F evaluated copanlisib, an α and δ isoform-specific phosphoinositide 3-kinase (PI3K) inhibitor, in patients with PIK3CA mutations (with or without PTEN loss)....The study met its primary end point with an ORR of 16% (P = .0341) with copanlisib showing clinical activity in select tumors with PIK3CA mutation in the refractory setting.
    DOI:
    10.1200/JCO.21.01648